Nasdaq:US$16.90 (-0.82) | HKEX:HK$27.20 (-0.95) | AIM:£2.52 (-0.11)
新闻中心及演示文稿
上一篇文章   |   下一篇文章
演示文稿, 科学出版物 | 2014-06-03

ASCO 2014: A phase 1b study of VEGFR inhibitor fruquintinib in patients with pretreated advanced colorectal cancer